Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-04-04
2006-04-04
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S212010, C514S307000, C514S409000, C514S412000, C514S423000, C514S563000
Reexamination Certificate
active
07022693
ABSTRACT:
An inhibitor of the renin-angiotensin system is useful for the treatment or prevention of the lipodystrophy syndrome, e.g. in AIDS patients also receiving anti-retroviral therapy.
REFERENCES:
patent: 2004/0082496 (2004-04-01), Acton et al.
patent: 2004/0087645 (2004-05-01), Scholkens et al.
patent: 0635263 (1994-05-01), None
patent: WO 99/20260 (1999-04-01), None
patent: WO 01/96347 (2001-12-01), None
Bonora, E. et al. “Effect of chronic treatment with lacidipine or lisinopril on intracellular partitioning of glucose metabolism in type 2 diabetes mellitus,”J. Clin. Endocrinolo. Metab. (1999), vol. 84, No. 5, pp. 1544-1550. Abstract from Database DrugU 'Online!.
Burns, G.C., et al. “Effect of Angiotensin-Converting Enzyme Inhibition in HIV-Associated Nephropathology,”Journal of the American Society of Nephrology(1997), vol. 8, No. 7, pp. 1140-1146.
Caldiz, C. et al. “Insulin Resistance in Adipocytes From Spontaneously Hypertensive Rats: Effect on Long-Term Treament with Enalapril and Losartan,”Metabolism(1999), vol. 48, No. 8, pp. 1041-1046.
Chisholm, D. et al. “Pathogenisis of the Insulin Resistance Syndrome (Syndrome X),”Clinical and Exp. Pharm. And Physiol. (1997), vol. 24, Nos. 782-784.
Chow, L. et al. “Blockade of angiotensin converting enzyme but not of angiotensin AT1receptors improves glucose tolerance,”European Journal of Pharmacology(1997), vol. 319, pp. 77-83.
Duong, M. et al. “Coronary Heart Disease associated with the use of human immunodeficiency virus (HIV)-1 protease inhibitors: Report of Four Cases and Review,”Clinical Cardiology(2000), vol. 24, pp. 690-694.
Egan, B. et al. “Effects of NaCl Restriction and Converting Enzyme Inhibition on Insulin and Blood Pressure in Hypersensitive Men with Upper Body Obesity,”Clin. Res. (1991), vol. 39, No. 2, pp. 432A.
Hardy, H. et al. “Glucose Disorders Associated with HIV and Its Drug Therapy,”Infectious Diseases(2001), vol. 35, pp. 343-351.
Hasslacher, C. “ACE-Hemmer bei metabolischem Syndrom,”Zeitschrift for Kardiologie(1994), vol. 83, Supplement 4, pp. 21-29.
Memon, A. et al. “Long term renal survival in HIV-associated nehropathy (HIVAN) with highly active antiretroviral therapy and angiotensin-converting enzyme inhibitors (ACEI),”Journal of the American Society of Nephrology(2000), vol. 11, Program and Abstract Issue, p. 91A.
Narciso, P. et al. “Metabolic and Morphologic Disorders in Patients Treated with Highly Active Antiviral Therapy since Primary HIV Infection,”Annals of the New York Academy of Sciences(Nov., 2001), vol. 946, pp. 214-222.
Nawano, M. et al. “Imidapril, an angiotensin-converting enzyme inhibitor, improves insulin sensitivityby enhancing signal transduction via insulin receptor substrate proteins and improving vascular resistance in the Zucker Fatty Rat,”Metabolism(1999), vol. 48, No. 10, pp. 1248-1255.
Radin, M. et al. “Treatement of Obese female an male SHHF/Mcc-facp rats with Antihypertensive Drugs, Nifedipine and Enalapril: Effects on Body Weight, Fat Distribution, Insulin Resistance and Systolic Pressure,”Obesity Research(1993), vol. 1, No. 6, pp. 433-442.
Suter, P. et al. “Metabolic Effects of Antihypertensive Drugs,”Journal of Hypertension(1995), vol. 13, Supplement 4, pp. S11-S17.
Verges, B. and Petit, J.M. “Anomalies lipidiques au cours des traitements par antiproteases,”Presse Med(2001), vol. 30, pp. 911-914.
Erusalimsky Jorge D.
Martin John Francis
Montgomery Hugh Edward
Ark Therapeutics Ltd.
Henley III Raymond J.
Saliwanchik Lloyd & Saliwanchik
LandOfFree
Treatment of lipodystrophy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of lipodystrophy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of lipodystrophy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3589549